Alector, Inc. develops clinical-stage biotechnology programs for neurodegenerative diseases, using genetics, immunology and neuroscience to pursue therapies that remove toxic proteins, replace missing proteins and restore immune and nerve cell function. News about ALEC commonly covers the Alector Brain Carrier (ABC) blood-brain barrier platform and ABC-enabled programs across antibodies, enzymes and siRNA.
Company updates focus on Alzheimer’s disease, Parkinson’s disease, Lewy body dementia, frontotemporal dementia and other tauopathies, including candidates such as AL137, AL050 and AL064/AL164, as well as prior clinical programs including nivisnebart and latozinemab. Recurring announcements also include financial results, cash runway commentary, clinical trial results or discontinuations, research pipeline progress, investor conference participation and executive leadership changes.
Alector (Nasdaq: ALEC) priced an underwritten common-stock offering expected to raise $75,030,000.00 in gross proceeds before underwriting discounts, commissions and estimated expenses.
The company is selling 36,600,000 shares at $2.05 per share, a premium of approximately 7.3% over the October 15, 2026 closing price. Alector expects the offering to close on or about October 19, 2026, subject to customary closing conditions. New and existing investors participating include TCGX, BVF Partners, ADAR1 Capital Management and Deep Track Capital. Alector anticipates using net proceeds for general corporate purposes, potentially including product development and manufacturing, working capital and complementary acquisitions or strategic transactions.
Alector (ALEC) will host a virtual research and development event on October 13, 2026, covering its wholly owned ABC-enabled pipeline. The webinar begins at 8:00 a.m. PT and will discuss Alector Brain Carrier, its platform for delivering therapies across the blood-brain barrier.
The agenda includes AL137, an anti-amyloid beta antibody, and the AL164, AL062 and ADP065 programs targeting tau, alpha-synuclein and NLRP3, respectively. Alector plans to present preclinical data on target reduction across multiple brain regions. A live question-and-answer session will follow the presentation, with an archived replay available for approximately 90 days.
Alector (Nasdaq: ALEC) entered an exclusive global licensing agreement with Genentech for AL050, with a $100 million upfront payment. AL050 is an investigational enzyme replacement therapy for Parkinson’s disease and other neurodegenerative diseases that uses Alector Brain Carrier (ABC) to deliver engineered GCase into the brain. Alector is eligible for up to $1.17 billion in additional development, regulatory and commercial milestone payments, plus tiered royalties on net sales.
Genentech will handle development, regulatory activities, manufacturing and commercialization across all indications. Alector retains ABC ownership and full rights to use it across its wholly owned pipeline. Alector expects the partnership to extend its cash runway into 2029, supporting its anti-Aβ antibody through multi-cohort clinical data in Alzheimer’s patients and its tau and alpha-synuclein siRNA programs through studies needed for investigational new drug filings.
Alector (ALEC) will participate in two investor healthcare conferences in New York in September 2026, each featuring a fireside chat with management.
The company joins the Cantor Global Healthcare Conference on September 10, 2026, at 2:10 p.m. ET and the Morgan Stanley 24th Annual Global Healthcare Conference on September 15, 2026, at 7:00 a.m. ET. Live webcasts and 90-day replays will be accessible via the Investors “Events & Presentations” page on Alector’s website.
Alector (Nasdaq: ALEC) reported second quarter 2026 collaboration revenue of $3.3 million, down from $7.9 million a year earlier, and a net loss of $23.0 million ($0.21 per share) versus a $30.5 million loss ($0.30 per share) in 2025.
Research and development expenses fell to $19.5 million from $27.6 million, and general and administrative expenses declined to $8.3 million from $14.4 million, reflecting prior reductions in force. As of June 30, 2026, cash, cash equivalents and investments totaled $172.8 million, which management expects will fund operations at least through 2027.
The company advanced its Alector Brain Carrier (ABC) blood-brain barrier platform, naming AL137 as its lead ABC-enabled anti-amyloid beta antibody for Alzheimer’s disease, with an IND filing targeted for Q1 2027 and first-in-human dosing in Australia no later than April 2027. Alector also progressed ABC-enabled siRNA candidates AL064/AL164 for tauopathies and AL050, an engineered GCase enzyme replacement therapy for Parkinson’s disease, which has shown preclinical activity and safety signals supportive of continued development.
Alector (Nasdaq: ALEC) reported Q1 2026 results and a business update on May 7, 2026. Cash, cash equivalents, and investments were $206.5 million as of March 31, 2026, which management expects will fund operations at least through 2027. The company advanced its Alector Brain Carrier (ABC) platform across antibodies, enzymes, and siRNA, highlighted IND-targeting timelines (AL037/AL137 targeted for Q1 2027), ongoing preclinical progress for AL050 and AL164, and discontinuation of the PROGRESS-AD Phase 2 nivisnebart trial after a prespecified interim futility analysis.
Q1 financials: collaboration revenue $1.0M, R&D $17.9M, G&A $8.1M, net loss $22.9M (≈$0.21/share).
Alector (Nasdaq: ALEC) will discontinue the Phase 2 PROGRESS-AD trial of nivisnebart (AL101/GSK4527226) in early Alzheimer’s disease after an independent data monitoring committee found the trial unlikely to meet its primary endpoint.
Alector and GSK will inform participants; full results will be shared at a future medical meeting. Alector says it will continue advancing multiple ABC-enabled programs with IND targets in 2027.
Alector (NASDAQ: ALEC) reported Q4 and full-year 2025 results and provided an update on its ABC brain-delivery platform and multiple preclinical and clinical programs. Cash, cash equivalents and investments totaled $256.0 million as of December 31, 2025, which management expects will fund operations at least through 2027.
Key program milestones include an independent interim futility analysis for PROGRESS-AD (nivisnebart/AL101) planned in 1H 2026 and IND timelines for ABC-enabled candidates AL137, AL050, and AL064 targeting 2026–2027 filings.
Alector (Nasdaq: ALEC) said management will present at the TD Cowen 46th Annual Health Care Conference on March 3, 2026 at 3:10 PM ET. A live webcast will be available on the company’s Investors “Events & Presentations” page, with a replay accessible for 90 days.
Alector (Nasdaq: ALEC) appointed Neil Berkley as Chief Financial Officer effective December 10, 2025. Berkley has served as Chief Business Officer since March 2024 and as Interim CFO since June 2025, and will continue to serve as CBO.
He brings more than two decades of experience in corporate strategy, finance, business development, fundraising, and operations across large pharma and biotech. Since joining in 2024 he helped advance strategic priorities, partnerships, and value-creation initiatives while supporting the company’s pipeline and ABC-enabled programs.